Findings

What do systematic reviews say?

300 questions · 309 findings · 25 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 53 · 17.2%GRADE not reported 11 · 3.6%Very low 41 · 13.3%Low 94 · 30.4%Moderate 80 · 25.9%High 30 · 9.7%

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1389 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1542 participants
Very low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Low

Aspirin vs placebo

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs placebo

Quality of life · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs placebo

Adverse event other than bleeding · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
5 participants
GRADE not reported

ASA with LMWH vs placebo or IVIG

Thrombosis · people with antiphospholipid antibodies and no history of thrombosis

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 258 participants
GRADE not reported

ASA with LMWH vs placebo or IVIG

Bleeding ‐ major (bleeding requiring transfusion) Length of · people with antiphospholipid antibodies and no history of thrombosis

ASA with LMWH showed no clear difference in bleeding ‐ major (bleeding requiring transfusion) Length of compared with placebo or IVIG (moderate certainty).

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
RR 9 [0.49, 164.76]
1 study · 180 participants
Moderate

ASA with LMWH vs placebo or IVIG

Bleeding ‐ other (bleeding during first trimester) Length of · people with antiphospholipid antibodies and no history of thrombosis

ASA with LMWH showed no clear difference in bleeding ‐ other (bleeding during first trimester) Length of compared with placebo or IVIG (moderate certainty).

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
RR 0.89 [0.5, 1.61]
1 study · 180 participants
Moderate

ASA with LMWH vs placebo or IVIG

Bleeding ‐ other (postpartum haemorrhage) Length of · people with antiphospholipid antibodies and no history of thrombosis

ASA with LMWH showed no clear difference in bleeding ‐ other (postpartum haemorrhage) Length of compared with placebo or IVIG (moderate certainty).

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
RR 1.3 [0.6, 2.81]
1 study · 180 participants
Moderate

ASA with LMWH vs placebo or IVIG

All‐cause mortality · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

ASA with LMWH vs placebo or IVIG

Quality of life · people with antiphospholipid antibodies and no history of thrombosis

The review found no eligible studies for this question.

1 finding from 1 review

Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found